While collaborations between CD8+IFNγ+ and CD4+IFNγ+ T cells are needed to kill tumor cells [28,29,30], several studies have reported that both of these cell types are suppressed in cancer patients during disease progression [31]. This evidence concerns the gene CD8A and neoplasm.